Healthcare Private Placement and M&A Transactions Review Week Ending Jan 28, 2024

Accent Therapeutics: The company raised $75 million of Series C venture funding in a deal led by Mirae Asset Capital Life Science on January 23, 2024, putting the company’s pre-money valuation at $100 million. GV, AbbVie Ventures, Timefolio Capital, Johnson & Johnson Innovation – JJDC, Bristol-Myers Squibb, Mirae Asset Venture Investment, The Mark Foundation for Cancer Research, The Column Group, Atlas Venture, EcoR1 Capital, Droia Ventures, Mirae Asset Capital, Mirae Asset Global Investments and other undisclosed investors also participated in the round. The company is a developer of cancer therapeutics intended to provide treatment using RNA structure, stability, function, and translation in cell biology.

Icotec: The company raised $30 million of venture funding from MVM Partners on January 24, 2024. The company is a developer of non-metallic spinal implants intended to treat spine cancer.

S2 Genomics: The company raised $16 million of Series A venture funding in a deal led by BroadOak Capital Partners and Research Corporation Technologies on January 23, 2024. The company is a developer of a spatial sequencing technology designed to provide products that process raw tissues into samples ready for genomic analyses.

G.ST Antivirals: The company raised EUR 4 million of Series A venture funding in a deal led by xista science ventures on January 25, 2024. The company is a developer of antiviral therapies against different viruses designed to help cure unmet diseases.

Siftwell: The company raised $4.1 million of venture funding from Tau Ventures and other undisclosed investors on January 23, 2024. The company is an operator of a healthcare predictive analytics company intended to identify members at high risk for rising costs, declining health, membership churn, and other business use cases.

AiCure: The company raised $4 million of venture funding from undisclosed investors on January 24, 2024. The company is a developer of an advanced data analytics platform designed to monitor patients’ behavior.

View Point Medical: The company raised $3.7 million of venture funding in the form of convertible debt from undisclosed investors on January 23, 2024. The company is a developer of a medical device created to empower early-stage lung disease prevention.

Novian Health: The company raised $2.2 million of venture funding in the form of convertible notes from undisclosed investors on January 22, 2024. The company is an operator of a proprietary medical technology platform intended to help in the treatment of tumors for early-stage breast cancer using interstitial laser therapy.

Pursuant Health: The company raised $2.1 million of venture funding from undisclosed investors on January 24, 2024. The company is a provider of health screening kiosks intended to allow individuals to regularly check in on their health.

Rimidi: The company raised $2 million of venture funding in the form of convertible debt from an undisclosed investor on January 24, 2024. The company is a developer of cloud-based software designed to enable chronic disease management.

ObjectiveHealth: The company raised an undisclosed amount of venture funding from Vitruvian Partners on January 26, 2024. The company is a developer of a clinical research platform intended to improve patient outcomes at the point of care.

Mirati Therapeutics / Bristol-Myers Squibb: The company was acquired by Bristol-Myers Squibb for approximately $5.8 Billion on January 23, 2024. Mirati Therapeutics Inc is a clinical-stage oncology company developing novel therapeutics to address the genetic and immunological promoters of cancer.

Inhibrx / Sanofi: The company reached a definitive agreement to be acquired by Sanofi for $2.2 billion on January 23, 2024. Inhibrx Inc is a clinical-stage biotechnology company focused on developing a pipeline of novel biologic therapeutic candidates.

Coherus BioSciences / Sandoz International: Sandoz International reached a definitive agreement to acquire the Coherus Biosciences for $170 Million on January 22, 2024. The company is a developer of biosimilar products catering to treating neovascular age-related macular degeneration, diabetic macular edema and diabetic retinopathy.

Oxitope Pharma / Calluna: The company was merged with Arxx Therapeutics to form Calluna on January 22, 2024. The company is a developer of antibody and gene therapy products intended for inflammatory and cardiovascular diseases.

Psyence Biomed / Newcourt Acquisition: The company, a subsidiary of Psyence Group, acquired Newcourt Acquisition through a reverse merger, resulting in the combined entity trading on the Nasdaq Stock Exchange under the ticker symbol PBM on January 25, 2024. Psyence Biomedical Ltd is a life science biotechnology company pioneering the use of natural psychedelics in mental health and wellbeing.

Intrahealth Systems / Healwell AI: The company, a subsidiary of WELL Health Technologies reached a definitive agreement to be acquired by Healwell AI for $24.2 million on January 25, 2024. The company is a developer of medical software solutions to provide access to virtual care/telehealth solutions.

Scout Bio / Ceva Sante Animale: The company was acquired by Ceva Sante Animale, via its financial sponsors AQUITI Gestion, Continental Grain Company, EMZ Partners, Hopu Investment Management and Mérieux Equity Partners, through an LBO on January 25, 2024 for an undisclosed amount. The company is a developer of vector-delivered protein therapeutics designed for veterinary medicine through one-time therapies.

ZoBio / Oncodesign Services: The company was acquired by Oncodesign Services, via its financial sponsors Edmond de Rothschild Group and Eurazeo, through an LBO on January 22, 2024 for an undisclosed amount. The company is a provider of drug discovery services catering to the pharmaceutical and biotechnology industries.